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Randomized clinical trials have demonstrated that carotid endarterectomy (CEA) is superior to medical management for stroke prevention
in patients with symptomatic and, to a lesser degree, asymptomatic internal carotid artery stenosis. However, large-scale registries have
shown that the adverse event rates following CEA are commonly higher than observed in the trials. In the last decade, carotid artery stenting
(CAS) has emerged as a less invasive alternative to surgery. In order to address the efficacy of CAS, we performed a meta-analysis of 10
randomized trials comparing CAS with CEA in 4648 mainly symptomatic patients. The analysis showed that CAS was associated with a stat-
istically significant increased death or stroke rate at 30 days compared with CEA (odds ratio 1.60, 95% confidence interval 1.26–2.02).
However, most of the trials had inadequate requirements in terms of endovascular expertise and did not mandate the use of emboli protec-
tion devices. Beyond 30 days, long-term follow-up of the trials previously reported suggest that both revascularization techniques are equiv-
alent in terms of stroke prevention. Conversely, large-scale high-quality CAS registries—mostly with independent neurological assessment
and clinical event committee adjudication—have reported results in the range of current recommendation for CEA in over 20 000 patients,
despite the fact that the majority of patients were at high risk for surgery. Until further data become available, the performance of CAS
should be limited to protocols or centres of excellence and targeted especially to patients at high risk for surgery.
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Introduction
In Western countries, stroke is the third most frequent cause of death,
behind cardiac disease and cancer, and is the number one condition
associated with permanent disability. An atherosclerotic lesion of
the internal carotid artery may be responsible for 10–20% of all
ischaemic strokes or transient ischaemic attacks (TIAs).1 Large-scale
randomized trials have established the benefit of carotid endarterect-
omy (CEA) over medical management in patients with symptomatic
and, to a lesser degree, asymptomatic carotid artery disease. In the
last decade, carotid artery stenting (CAS) has been increasingly advo-
cated as less invasive treatment to surgery. This review focuses on the
current role of both revascularization techniques.
Carotid endarterectomy
Impact of technique on outcomes
The performance of carotid CEA has undergone significant revi-
sion and modification over the last 50 years. Improvements in
the technique and post-procedural care have made CEA a rela-
tively simple surgery characterized by a low stroke risk, limited
morbidity, and rapid recovery. Typically, patients are operated
while on aspirin 100–325 mg/day. The operation is performed
under regional or, more commonly, general anaesthesia. The
General Anesthesia vs. Local Anesthesia for carotid surgery
(GALA) trial randomized 3526 patients undergoing CEA to the
two forms of anaesthesia and found no difference in stroke or
mortality rates.2
Surgery is usually started by means of an oblique incision along
the anterior border of the sternocleidomastoid muscle, which is
then retracted posteriorly exposing the common carotid artery,
the carotid bifurcation, the external carotid artery, the superior
thyroid artery, and the internal carotid artery (Figure 1). Thereafter,
intravenous heparin is administered to achieve full anticoagulation,
and the internal, external, and common carotid arteries are
clamped. If needed, a shunt is placed at that time. Following a longi-
tudinal incision from the common carotid artery into the internal
carotid artery, the plaque is removed and the arteriotomy is
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repaired with the use of a patch. Although primary closure of the
endarterectomy site is still performed by a number of surgeons,
there is strong evidence in favour of routine patch placement for
the reduction of acute stroke risk and recurrent stenosis.3 An
alternate to standard approach, endarterectomy can also be per-
formed using an eversion technique. Eversion and conventional
endarterectomy have been proved to be associated with similar
outcomes in a randomized comparative trial involving 1353
patients.4 Following CEA, the patient is usually monitored in a
post-anaesthesia care unit. Although the mean length of hospital
stay may vary in different countries, a discharge on post-operative
day 1 or 2 has proved to be feasible and safe.5
Randomized trials on carotid
endarterectomy vs. medical management
The current treatment of extracranial cerebrovascular disease has
been based on major randomized controlled trials comparing
medical management and CEA on the occurrence of stroke or
death. In symptomatic patients, CEA offered a profound benefit
over medical therapy as demonstrated in North American Sympto-
matic Carotid Endarterectomy Trial (NASCET)6,7 and European
Carotid Symptomatic Trial (ECST)8 (Table 1). NASCET reported
a dramatic benefit of surgery in terms of stroke prevention for
symptomatic carotid stenosis 70% with an absolute risk
Figure 1 Technique of carotid endarterectomy. An atherosclerotic lesion involving the common carotid artery (CCA), internal carotid artery
(ICA), and external carotid artery (ECA) is demonstrated on the left panel. The middle panel demonstrates plaque removal following a longi-
tudinal incision of the vessel. The right panel shows the arteriotomy repair with the use of a patch.
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Table 1 Randomized controlled trials evaluating medical management vs. carotid endarterectomy for ipsilateral
stroke prevention in patients with carotid artery stenosis
Degree of stenosis (%) Medical Rx CEA (%) Medical Rx (%) RRR/ARR (%) NNT Endpoint*
Symptomatic population
NASCET6 70–99 Aspirin 1300 mg daily 9.0 24.5 65/15.5 6 2-year stroke risk
NASCET7 50–69 Aspirin 1300 mg daily 15.7 22.2 29/6.5 15 5-year stroke risk
ECST8 70–99 Not specified 7.0 19.9 65/12.9 8 3-year stroke risk
Asymptomatic population
VA11 50–99 Aspirin 650 mg twice daily 4.7 9.4 50/4.7 23 5-year stroke risk
ACAS9 60–99 Aspirin325 mg daily 5.1 11.0 53/5.9 17 5-year stroke risk
ACST10 60–99 Antiplatelet drugs 6.4 11.8 46/5.4 18 5-year stroke risk
CEA, carotid endarterectomy; Rx, treatment; RRR, relative risk reduction; ARR, absolute risk reduction; NNT, number needed to treat to prevent one stroke; VA, Veteran’s
Administration Cooperative Study; ASA, aspirin; ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surgery Trial; NASCET, North American
Symptomatic Carotid Endarterectomy Trial; ECST, European Carotid Symptomatic Trial.
*Kaplan-Meier estimates.
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reduction (ARR) of 16.5% over 2 years and a significant but less
marked advantage in patients with 50–69% carotid stenosis
(ARR 6.5% over 5 years).6,7 Similarly, ECST reported an ARR of
stroke of 12.9% over 3 years associated with CEA for patients
with symptomatic carotid stenosis 70% (measured according
to the ECST method and approximately equivalent to 50% ste-
nosis as measured in NASCET).8
The benefit of CEA in asymptomatic individuals has been less
impressive. Three major trials have evaluated surgery in compari-
son with medical treatment in this setting, namely ACAS (Asymp-
tomatic Carotid Atherosclerosis Study),9 ACST (Asymptomatic
Carotid Surgery Trial),10 and VA (Veterans Administration Coop-
erative Study).11 The minimum degree of stenosis to qualify for
the study was 50% in the VA study and 60% in ACST and ACAS.
In the trials, the 30-day stroke and mortality rate was 3% in sur-
gically treated patients. Since the stroke rate among asymptomatic
patients medically treated in ACAS and ACST was low, 2% per
year, the ARR conferred by CEA in these trials was in only the
range of 1% per year despite an RRR in the range of 50%. This
translates into number needed to treat in the range of 100 to
prevent one stroke per year with surgery.3,7
Limitations of randomized clinical trials
The role of revascularization in asymptomatic patients has been
challenged because of outdated medical regimen used in the ran-
domized trials, and specifically the lack of statin therapy. ACST
was the only trial in which patients were at least in part treated
with a lipid-lowering agent (17% at the time of randomization,
70% at their last follow-up visit).10 Indeed, aggressive lipid-lowering
treatment could further reduce the benefit of surgery in asympto-
matic patients, eliminating the benefit of intervention in some
cases.12 However, although for most patients with asymptomatic
carotid artery stenosis the yearly risk of stroke may be in the
range of 1–2%,9,10 the risk may increase to 3–4% per year in
elderly patients or in the presence of contralateral carotid stenosis
or occlusion, carotid plaque heterogeneity, poor collateral blood
supply, generalized inflammatory states, or cardiac or medical
illnesses.13 Therefore, the benefit of revascularization may have
been underestimated in selected subgroups of patients.
Finally, it is unknown whether the surgical results observed in
the randomized trials may apply to the large proportion of patients
who fall outside the inclusion criteria for the trials or for surgeons
and centres not involved in the studies. For example, in both ACAS
and NASCET patients beyond the age of 79 years, with a life
expectancy of ,5 years, surgery in the last month, unstable
angina, cardiac valvular disease, symptomatic heart failure, pulmon-
ary failure, renal failure, and cancer were excluded from enrol-
ment. Anatomic exclusion criteria included previous ipsilateral
CEA, tandem lesions, radical neck surgery, and prior neck radiation
therapy.6,14 Patient’s characteristics known to increase the surgical
risk are reported in Table 2. Another limitation on the generaliz-
ation of the trials’ results is that surgeons in these studies were
vetted prior to initiating enrolment, were well experienced with
the procedure, outcomes were monitored carefully throughout
the studies, and enrolment was limited or even discontinued at
poorly performing sites.
Therefore, results of CEA observed in the clinical trials may not
represent everyday clinical practice. An analysis involving 10 561
patients undergoing CEA across different states in the USA docu-
mented a 30-day mortality of 1.5% and a stroke or mortality rate of
5.2%.15 The mortality rate was 1.6% in symptomatic patients and
1.1% in asymptomatic patients. The stroke or mortality rate was
7.5% in symptomatic patients and 3.7% in asymptomatic patients,
both beyond the thresholds recommended by the American
Heart Association (AHA) guidelines, described in what follows.16
Similar results were observed in a registry from Ontario Canada
documenting a 30-day death or stroke rate of 6.0% among 6038
patients undergoing surgery, with an event rate of 7.3% among
symptomatic and of 4.7% among asymptomatic patients.17
Guidelines and consensus documents
on carotid endarterectomy
Numerous groups have outlined recommendations regarding the
performance of CEA. The most widely quoted guidelines are
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Table 2 Conditions associated with an increased operative risk for carotid endarterectomy
Anatomic factors Medical factors
Prior CEA Class III or IV heart failure
Prior neck surgery Non-revascularized left main or multivessel coronary disease
Prior neck irradiation Class III or IV angina
Symptomatic ICA lesion Myocardial infarction within 30 days
High ICA lesion Severe renal insufficiency
Low CCA lesion Age 80
Tracheostomy Severe pulmonary disease
Contralateral laryngeal nerve palsy Female sex
Contralateral ICA occlusion Concomitant cardiac surgery
Intraluminal thrombus Recent implantation of a coronary drug eluting stent
Long subtotal ICA occlusion (string sign)
CEA, carotid endarterectomy; ICA, internal carotid artery; CCA, common carotid artery.
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those produced by the AHA, likely because they are multidisciplin-
ary, involving neurologists, surgeons, and cardiologists.16 Across
the different documents, there is agreement on the strong evi-
dence in favour of performing CEA in symptomatic patients with
70% stenosis, provided the surgical risk of stroke or death is
kept at ,6%. For symptomatic patients with ,50% stenosis,
there is no benefit from surgery. In patients with symptomatic
50–69% stenosis, a moderate benefit from CEA is present, and
the decision to proceed should be based on the surgical risk and
life expectancy of the patient as well as on the local surgical exper-
tise. According to the AHA guidelines, there are no proven but
only acceptable indications for CEA for symptomatic patients
with an estimated peri-operative risk of stroke or death .6%.
Those indications include TIA or mild-to-moderate stroke within
a 6-month interval and 70% carotid stenosis; recurrent TIA
while on anti-platelet therapy with 50% ulcerated carotid steno-
sis; crescendo TIA with 50% carotid stenosis; and evolving stroke
in the presence of 70% carotid stenosis with large ulceration.16
Guidelines recommend CEA in asymptomatic patients for
patients with 60% stenosis.16,18 However, the benefit is moder-
ate and present only if the surgical risk of death or stroke is kept at
,3% and life expectancy of the patient is at least 5 years. Lesion,
patient, and surgeon characteristics should be taken into account in
the decision process involving asymptomatic individuals. The 2005
guidelines of the American Academy of Neurology recommend
revascularization in eligible asymptomatic patients only up to the
age of 75 years.18
Carotid artery stenting
Patients undergoing CAS are commonly pre-treated with aspirin
and clopidogrel. Aspirin is continued lifelong and clopidogrel
given for at least 1 month after the procedure. The concept of
dual antiplatelet therapy came from the coronary experience and
was immediately embraced by part of the interventional commu-
nity also for the endovascular treatment of the carotid arteries.
Small randomized trials comparing single with double antiplatelet
therapy for CAS followed but had to be prematurely terminated
due to high stent thrombosis and neurological event rates in the
aspirin-only group.19,20 Anticoagulation, commonly with unfractio-
nated heparin, is limited to the time of the procedure.
The common carotid artery is engaged with a guiding catheter
or a long sheath. At this time, an emboli protection device
(EPD) is deployed. Three types of EPDs are available: filter-based,
distal balloon occlusion and the proximal occlusion EPD—with or
without flow reversal (Figure 2). Although the use of EPDs has
never been investigated in a randomized fashion, there is
broad—though not unanimous—consensus that these devices
should be used during CAS.21– 23 A systematic review documented
a 30-day death or stroke rate of 5.5% among 2357 patients under-
going CAS without the use of EPDs and of 1.8% among 839 indi-
viduals treated with these devices (P, 0.001).24 A benefit from
EPDs was also suggested in a large-scale prospective registry doc-
umenting an in-hospital death or stroke rate of 2.1% among 666
patients undergoing CAS with adjunctive EPDs and of 4.9% in
Figure 2 Strategies for emboli protection devices in carotid artery stenting. On the left panel, a filter device is demonstrated; in the middle, a
distal balloon occlusive device; and in the right panel, a proximal occlusive device. CCA, common carotid artery; ICA, internal carotid artery;
ECA, external carotid artery.
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the group of patients (n ¼ 789) treated without protection (P ¼
0.004).25 In the same study, the use of EPDs was identified in the
multivariate analysis as an independent protective factor for this
endpoint [adjusted odds ratio (OR) 0.45; P ¼ 0.026]. Similar find-
ings were observed in a prospective multicentre feasibility trial
enrolling 261 patients.26 Accordingly, the 1 year major ipsilateral
stroke rate was 0% among patients undergoing CAS with adjunc-
tive EPDs and 2.3% in patients undergoing unprotected CAS
(P ¼ 0.05). As a confounding variable, EPDs have been used
more recently and therefore likely at a later stage of the operator’s
learning curve. Nevertheless, even in centres with large CAS
experience prior to the introduction of these devices, the use of
EPDs did affect outcomes positively.27,28 The complication rate
associated with EPD use appears to be low (,1%).29 In the
USA, CAS without the use of EPDs is not reimbursed. Filter-based
systems are the most widely used type of EPDs on both sides of
the Atlantic.
Although no randomized study has compared carotid angio-
plasty vs. stenting, virtually all endovascular carotid procedures
currently performed are stent-based (Figure 3). Carotid stents
are self-expanding and the vast majority of them are made of
nitinol. With respect to stent design, carotid stents are available
in closed-cell and open-cell designs. Although from a conceptual
perspective closed-cell design may confer better plaque coverage
than open-cell design and be advantageous for the treatment of
symptomatic lesions, no randomized comparison has been per-
formed so far, and the existing reports are conflicting.30,31 Follow-
ing stent deployment, a post-inflation of the stent with a balloon
catheter is mandatory. Subsequently, the EPD system and then
the guiding catheter/sheath are removed.
Strengths and limitations of carotid
artery stenting
The main advantages of CAS over CEA are that the procedure
is less invasive, performed under local anaesthesia, and is less
influenced by the co-morbidities of the patient, while the out-
comes are determined mainly by anatomical or procedural
variables.32– 34 In addition, patients are usually discharged the day
following the procedure. Factors associated with an increased
risk or being considered a contraindication for CAS are listed in
Table 3. As for CEA, CAS carries a higher risk of stroke if per-
formed in symptomatic patients compared with asymptomatic
patients.32,33 In addition, octogenarians have been identified as a
high-risk subgroup in CAS and age has been detected as indepen-
dent predictor of adverse events in large-scale registries.33,35 The
likely explanation for this finding is that older patients have more
advanced atherosclerotic disease and complex anatomy at the
level of the aortic arch and supra-aortic vessels, such as a steep
aortic arch or severe tortuousity of the common carotid arteries.
As a result, the engagement of the common carotid artery with
guiding catheters or sheaths may be more cumbersome and
cause distal embolization. Nevertheless, a recent single-centre
experience has demonstrated that in selected octogenarians with
favourable anatomy, CAS can be accomplished at a complication
rate below the standard recommended for CEA in the general
population.36
An additional advantage of CAS over CEA is that the endovascular
approach allows for the treatment of lesions not accessible to surgery,
such as those located high in the internal carotid artery or low in the
common carotid artery. However, this disease pattern affects only a
Figure 3 Carotid artery stenting procedure. Following engagement of the common carotid artery (CCA) with a guiding catheter or long
sheath, the lesion in the internal carotid artery (ICA) is passed with a wire or with the filter emboli protection device (A). Subsequently, a
self-expanding stent is deployed, usually covering the carotid bifurcation (B and C). Thereafter, a balloon post-dilatation is performed to
achieve good stent expansion (D). ECA, external carotid artery.
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minority of patients. Conversely, CEA may be the treatment of choice
for patients with poor or no femoral access. Accordingly, although
CAS may be performed using a radial or brachial approach, the
access and engagement of the common carotid arteries are
complex and likely associated with higher complication rates.
Since EPDs are believed, as discussed previously, to improve
outcomes in CAS, the inability to place such a device should
also be considered a relative contraindication to stenting.
However, this is rarely the case because of the different types of
EPDs available. Commonly recognized contraindications to CAS
include a severe circumferential calcification at the level of the
carotid lesion, which may limit stent expansion, and the presence
of a thrombus.21 Finally, on the basis of the critical role of dual anti-
platelet therapy in CAS, in patients with proven intolerance to
aspirin or clopidogrel, surgery should be preferred.
Like in any other endovascular or surgical procedure, common
sense suggests a major impact of operator skills and experience
on CAS outcomes. However, these variables are difficult to inves-
tigate other than in a simulator setting.37 Nevertheless, in the
PRO-CAS registry, the procedural stroke and death rates
decreased over time and differed according to the level of experi-
ence with a 5.9% stroke/death rate in centres with less than 50
interventions per year and a 3.0% rate in those with more than
150 interventions per year.32 Similarly, centres reporting less
than 50 interventions per year in a randomized trial had a
stroke/mortality rate of 4.6%, whereas those performing more
than 50 procedures had a stroke/mortality rate of 2.9%.38 In the
CASES-PMS registry, in which investigators underwent a compre-
hensive training programme prior to patient enrolment, no differ-
ence in outcomes was observed in relation to the baseline CAS
experience.39 This suggests that such a programme may help in les-
sening the learning curve.
Randomized trials of carotid
endarterectomy vs. carotid artery
stenting
Five major, i.e. including more than 300 patients, randomized trials
have compared endovascular and surgical carotid revascularization.
Whereas the SAPPHIRE (Stenting and Angioplasty with Protection
in Patients at HIgh Risk for Endarterectomy) trial40 focused on
patients—both symptomatic and asymptomatic—at high risk for
surgery, CAVATAS (CArotid and Vertebral Artery Transluminal
Angioplasty Study),41 SPACE (Stent protected Percutaneous
Angioplasty of the Carotid artery vs. Endarterectomy),42 EVA-3S
(Endarterectomy vs. Angioplasty in patients with Symptomatic
Severe carotid Stenosis),43 and ICSS (International Carotid Stent-
ing Study)44 enrolled exclusively symptomatic patients.
The CAVATAS study, performed in the late 1990s, randomized
504 symptomatic patients at low-to-moderate risk for surgery to
CEA or carotid angioplasty.41 The incidence of death or stroke
at 30 days was 10.0% in the endovascular group and 9.9% in the
surgical group. The outcomes among the two groups remained
comparable at 3 years.
The SAPPHIRE study is the only randomized trial comparing
CEA and CAS performed with the systematic use of EPDs.40
The trial included symptomatic and asymptomatic patients at
high risk for surgery and was designed to prove the non-inferiority
of the endovascular approach. The study was terminated prema-
turely because of slow enrolment owing to competing CAS regis-
tries. Among the 334 patients randomized (29% of them being
symptomatic), major adverse events at 1 year occurred in 12.2%
in the CAS group and in 20.1% in the CEA group (P ¼ 0.053).
In the actual treatment analysis, the observed difference reached
statistical significance (P ¼ 0.048). The difference was mainly
driven by a reduction in the rate of myocardial infarction (at
30 days 0.6% in the CAS group vs. 4.3% in the CEA group; P ¼
0.04). No cranial nerve injury was observed in the CAS group,
whereas this complication occurred in 5.3% of the CEA patients
(P, 0.01). The durability of CAS was documented by a compar-
able cumulative percentage of major (1.3% for CAS vs. 3.3% for
CEA) and minor (6.1% for CAS vs. 3.0% for CEA) ipsilateral
strokes at 3 years as well as by a low rate of repeat revasculariza-
tion during the same period of time (3.0% for CAS vs. 7.1% for
CEA).45
The SPACE study sought to prove the non-inferiority of CAS
compared with CEA among symptomatic patients. The use of
EPDs in the CAS arm was left at the discretion of the treating
physician and was used in 27% of cases. Although the required
sample size based on interim analysis was 2400 patients, the trial
had to be terminated following the inclusion of 1200 patients
because of slow enrolment and lack of funding. The incidence of
ipsilateral stroke or death at 30 days was the primary endpoint
of the study and did not differ between the groups, occurring in
6.8% of cases in the endovascular group and in 6.3% of patients
in the surgical arm.42 At 2-year follow-up, no difference in
adverse events between the two groups could be detected.46
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Table 3 Conditions associated with increased
procedural risk and contraindications for carotid artery
stenting
Increased risk
Age 80 years
Symptomatic ICA lesion
Severe renal insufficiency
Severely diseased and/or steep aortic arch
Severely diseased and/or tortuous CCA
Severely diseased and/or tortuous distal ICA
Long subtotal ICA occlusion (string sign)
Poor femoral access
Major stroke within 4–6 weeks
Extensive intracranial microvascular disease
Contraindications
Intolerance to aspirin and/or clopidogrel
Circumferential ICA calcification
Intraluminal thrombus
Chronic ICA occlusion
Intracranial aneurysm or AVM requiring treatment
CCA, common carotid artery; ICA, internal carotid artery; AVM, arteriovenous
malformation.
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The EVA-3S was a randomized non-inferiority trial comparing
CAS with CEA in patients with a 60% symptomatic carotid
artery stenosis. The primary endpoint was the cumulative inci-
dence of any stroke or death within 30 days after treatment.43
The protocol did not mandate the use of EPDs. The performance
of CAS without EPD protection in the study was rapidly halted fol-
lowing the observation that 4 out of 15 patients treated without
protection suffered a stroke, whereas the proportion of patients
treated with protection was 5 out of 58 [OR 3.9; 95% confidence
interval (CI) 0.9–16.7].47 The entire trial was then stopped prema-
turely after the inclusion of 527 patients because of significantly
increased event rates in the CAS arm (death or stroke 9.6% in
the CAS arm and 3.9% in the CEA arm; P ¼ 0.01). At
6 months, the incidence of any stroke or death was 11.7% in the
CAS group and 6.1% in the CEA group (P ¼ 0.02). At 4-year
follow-up, the death or stroke rate still favoured CEA, driven by
the 30-day events. Beyond 30 days, no difference was observed.48
The International Carotid Stenting Study (ICSS) randomized
1710 symptomatic patients to CAS or CEA.44 The primary end-
point is the long-term survival free of disabling stroke. The use
of EPDs was not mandatory. Although follow-up is ongoing and
expected to be completed in 2011, the 30-day safety results
were recently presented.49 The incidence of death, stroke, or peri-
procedural myocardial infarction was 8.5% in the CAS group and
5.1% in the CEA group (P ¼ 0.004). No difference was observed
in the survival free of disabling stroke at 120 days.
Limitations of randomized clinical trials
Current randomized data comparing CAS and CEA have several
limitations. First of all, the data on asymptomatic patients are
limited since all but one trial included only symptomatic patients.
Second, the use of EPDs was mandatory in just one trial. Third,
the minimal endovascular experience required per protocol was
in most of the trials incredibly low, raising important questions
on the ethics of the studies and applicability of the results
(Table 4). This despite the observation that in the first randomized
trial, a single-centre study, the inexperience of the operator ( just
eight CAS procedures) had catastrophic results on CAS out-
comes.50 Out of seven patients undergoing CAS, five had a
stroke, and the study was prematurely discontinued. Of note, in
all but one large-scale trial, tutoring was allowed.
In CAVATAS, training in neuroradiology and angioplasty (but not
necessarily in the carotid artery) was required, and tutor-assisted
procedures were allowed for investigators with little skill in cer-
ebrovascular angioplasty.41 In SAPPHIRE, the most demanding in
terms of previous endovascular experience, investigators had to
submit their procedures to an executive review committee, and
the CAS peri-procedural death or stroke rate had to be ,6%
and no tutor-assisted procedures were allowed.40 With respect
to the SPACE trial, the main publication described a minimum of
25 successful consecutive percutaneous transluminal angioplasty
or stenting procedures.42 However, a second publication reveals
that during the trial, an amendment of the protocol allowed for
tutoring of interventionalists who had a total experience of at
least 10 CAS procedures.51
In the French EVA-3S study, the minimal endovascular require-
ment was 12 CAS procedures. Alternatively, a minimum of five
interventions was deemed to be sufficient to enrol if the operator
had performed in his lifetime at least 35 stenting procedures of the
supra-aortic trunks. Finally, for investigators not meeting those
requirements, it was possible to perform the procedure under
the supervision of an experienced tutor—defined as someone
with an experience of at least 12 CAS procedures.43,52 In a later
correspondence, the EVA-3S investigators stated that in the trial,
only 16% of patients were treated by interventionalists having per-
formed more than 50 CAS procedures in their lifetime, and 39% of
patients were treated by physicians in training.53 Indirect evidence
of the suboptimal endovascular treatment of patients in EVA-3S is
derived from the incomplete coverage with dual antiplatelet
therapy (83% pre-procedure and 85% post-procedure), as well
as the high rate of emergent conversion from CAS to CEA (5%),
an exceedingly rare complication. A critical question is how inter-
ventionalists could have gathered sufficient experience at all if, in
France, CAS was never reimbursed. In ICSS, a minimum of 50
total stenting procedures, of which at least 10 had to involve the
carotid artery, was required.44 Tutor-assisted procedures were
allowed for interventionalists with insufficient experience.
It remains unanswered why these soft requirements with
respect to endovascular experience were proposed by the trial
leaderships and accepted by Ethical Committees. Other than SAP-
PHIRE, none of the randomized trials would have satisfied the
minimum recommended experience according to a multispecialty
CAS clinical competence statement.54 The least to say, in the
Table 4 Requirements in terms of endovascular expertise in randomized trials enrolling more than 300 patients and
comparing carotid endarterectomy and stenting
CAVATAS41 Training in neuroradiology and angioplasty (but not necessarily in the carotid artery) required. Tutor-assisted procedures allowed
SAPPHIRE40 Procedures submitted to an executive review committee; CAS peri-procedural death or stroke rate had to be ,6%
No tutor-assisted procedures allowed
SPACE42,51 At 25 successful CAS cases or assistance of a tutor for interventionalists having performed at least 10 CAS cases
EVA-3S43 12 or more CAS cases or 5 or more CAS cases and 30 or more cases of endovascular treatment of supra-aortic trunks. Tutor-assisted CAS
allowed for centres not fulfilling minimal requirements
ICSS44 A minimum of 50 total stenting procedures, of which at least 10 should be in the carotid artery. Tutor-assisted procedures allowed for
interventionalists with insufficient experience
CAS, carotid artery stenting.
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design of the trials, the main purpose of randomized testing of a
new procedure was missed, namely to show that the therapy is
efficacious in the hands of the most skilled operators on selected
(favourable) patients. In this respect, early testing of CEA against
medical therapy was properly conducted. In ACAS for example,
patients at high risk for surgery were excluded from the trial,
and both the centres and the individual surgeons had to demon-
strate a 30-day death or stroke rate of ,3.0% to be able to
enrol. In addition, during the study, the surgeons were audited in
the presence of more than one complication and were allowed
to continue enrolment only if no operator-related problem was
observed.9,14
Meta-analysis of the randomized trials
In order to define the current data on the efficacy of CAS vs. CEA,
we performed a meta-analysis of the randomized trials comparing
CEA and CAS and addressed the 30-day death or stroke rate. To
that purpose, we searched MEDLINE (January 1980–July 2009),
the Cochrane databases (January 1980–July 2009), EMBASE
(January 1980–July 2009), CINAHL (January 1982–June 2009),
the US Food and Drug Administration website (http://www.fda.
gov), and BIOSIS Previews (January 1980–July2009), using
database-appropriate terms for the following: carotid artery
disease, carotid angioplasty, carotid stenting, CEA, and carotid
revascularization. In addition, we sought studies by reviewing the
reference lists of eligible studies and relevant review articles.
Finally, major meeting abstract databases (AHA, American
College of Cardiology, European Society of Cardiology,
Euro-PCR, Transcatheter Cardiovascular Therapeutics, American
Stroke Association conference, and European Stroke Conference)
were searched using the search terms listed here. A study was
included if it randomized patients with carotid artery disease to
CAS or CEA and provided the 30-day death or stroke rate per
intention-to-treat analysis. Information was abstracted using a stan-
dardized form that included data on the study population and the
mentioned outcome.
The analysis was performed with the software provided by MIX
meta-analysis.55,56 The Peto fixed-effect model was used to calcu-
late ORs and 95% CIs. Probability values ,0.05 were considered
significant. Heterogeneity among trials was tested using Q and I2
test, and P, 0.1 was considered statistically significant for this
analysis. A total of 4648 patients, 2334 randomized to CAS and
2314 allocated to CEA, were enrolled in 10 trials. The Chinese
TESCAS-C trial enrolling 166 patients was not included because
it did not report death or stroke at 30 days.57 In ICSS, the analysis
was restricted to patients in which allocated treatment was
initiated. Patients undergoing CAS has a significant increase in
30-day death or stroke compared with patients treated surgically
(OR 1.60, 95% CI 1.26–2.02) (Figure 4). Statistical tests showed sig-
nificant heterogeneity in outcomes among the trials (heterogeneity
P ¼ 0.02). As pointed out in a recent Cochrane review, random-
ized data of CAS vs. CEA are difficult to interpret because of
the heterogeneity among the trials and because several trials
were stopped early—a factor that may have led to an overestima-
tion of the endovascular risk.58 A further limitation of this analysis
is the inclusion—for the sake of completeness—of smaller, single-
centre, non-controlled, randomized trials.
The added value of the present meta-analysis compared with
recent similar report is that it included the largest study of CAS
vs. CEA so far performed (ICSS). The recent Cochrane document
provided an excellent review of the randomized data but was
published before the results of ICSS were made available.58
Figure 4 Meta-analysis of the randomized trials comparing carotid artery stenting (CAS) with carotid endarterectomy (CEA). The trials are
Leicester,50 Wallstent,68 Kentucky-symptomatic,69 CAVATAS,41 Kentucky-asymptomatic,70 SAPPHIRE,40 EVA-3S,43 SPACE,42 BACASS,71 and
ICSS.49
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Brahmanandam et al.59 included two non-randomized studies in
their analysis, and the strength of the report of Gurm et al.45
was the presentation of long-term outcomes of the two revascu-
larization strategies.
Large-scale registries
The results of seven CAS registries enrolling more than 1000
patients have been published, for a total of 20 105 patients
(Table 5). All but one were performed in the USA, included
patients at high risk for surgery, and the majority of patients
included were asymptomatic. The good quality of the studies is
demonstrated by the high proportion of mandatory neurological
assessment pre- and post-procedure (four out of seven) and clini-
cal event committee adjudication of adverse events (five out of
seven). The use of EPDs was mandatory in five studies and used
in the majority of patients in the remaining two.
The PRO-CAS registry enrolled in German patients with vari-
able risk for surgery and reported an in-hospital death or stroke
rate of 3.6%.32 Symptomatic and asymptomatic patients had an
event rate of 4.3 and 2.7%, respectively. In the CAPTURE registry,
the 30-day stroke/mortality rate was 5.7% among 3500 patients,
with symptomatic individuals experiencing a stroke rate of 8.9%
and asymptomatic patients a rate of 4.1%.60 The CASES-PMS
registry-recorded outcomes in 1493 high-risk patients treated
with CAS utilizing EPDs reported a stroke/mortality rate of 4.5%,
with a stroke rate of 5.3% in symptomatic patients and 3.4% in
asymptomatic individuals.39 The SAPPHIRE Worldwide registry
reported a 30-day stroke or death rate of 4.0% in 2001 high-risk
patients, with a higher event rates in symptomatic compared
with asymptomatic patients (adjusted OR 2.4).61
The SVS registry reported 30-day outcomes among 1450
patients who underwent CAS and 1368 patients treated with
surgery.62 In this analysis, the CAS group had significantly higher
event rates than CEA (death, stroke, or myocardial infarction
rate 6.4 vs. 2.6%). This analysis was limited by the marked imbal-
ances among the groups, the ,50% collection of 30-day events,
the lack of systematic neurological assessment, and event adjudica-
tion as well as the different definition of myocardial infarction
among the centres.
The results of two large-scale registries enrolling patients at high
risk for surgery, the EXACT (n ¼ 2145) and the CAPTURE 2 (n ¼
4175) studies, were recently reported.63 The overall 30-day death
and stroke rate in the two studies were 4.1 and 3.4%, respectively.
In the population comparable with AHA guidelines (age ,80
years), the pooled analysis of the two registries denoted a death
or stroke rate within current recommendations for CEA, namely
5.3% for symptomatic patients and 2.9% for asymptomatic patients.
In patients 80 years of age, the death and stroke rates in sympto-
matic and asymptomatic patients were 10.5 and 4.4%, respectively.
Guidelines, consensus documents,
and reimbursement
Guidelines of the AHA and the American Stroke Association pub-
lished in 2006 stated that in symptomatic patients with severe ste-
nosis (.70%) in whom the lesion was difficult to access surgically,
medical conditions were present that greatly increase the risk for
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surgery, or when other specific circumstances existed such as
radiation-induced stenosis or restenosis after CEA, CAS was not
inferior to CEA and may be considered.64 In addition, they
stated that CAS was reasonable when performed by operators
with established peri-procedural morbidity and mortality rates of
4–6%. The American Society for Vascular Surgery proposed
CAS as a potential alternative for symptomatic patients with high
peri-operative risk.65 Although there was consensus agreement
among the authors regarding parameters defining high anatomic
risk, no consensus was reached with respect to the definition of
high-risk medical criteria. In addition, the authors of the guidelines
recommended against the use of CAS for asymptomatic stenosis, a
‘low-quality’ recommendation based on the lack of randomized
data in this setting. According to the 2009 guidelines of the
European Society of Vascular Surgery (ESVS), CAS should be
performed only in high-risk CEA patients, in high-volume centres
with documented low peri-operative stroke and death rates or
inside a randomized controlled trial.22
An American consensus paper endorsed by cardiological, radio-
logical, as well as vascular medicine societies stated that (i) CAS
could be considered as an alternative to CEA in patients with
symptomatic stenosis at high risk for CEA, and (ii) CAS was
reasonable when performed by operators with established peri-
procedural morbidity and mortality rates of 4–6%.21 A position
paper of the German Cardiology Society and German Angiology
Society extended the use of CAS also to patients not at high
risk for surgery.66 An Italian consensus involving cardiologists, vas-
cular surgeons, radiologists, and neurologists stated that CAS
should be used instead of CEA for patients at high risk for
surgery, and CAS may be performed in patients not at high risk
for surgery if the complications rates are within the AHA rec-
ommendations for CEA.23
Several other CAS consensus documents, on both sides of the
Atlantic, have focused more on credentialing, highlighting the
‘turf battles’ that have plagued the advancement of this interven-
tion since its inception and technological development.23,54,67 All
groups recommended specific training not limited to catheter
skills but including all aspects of carotid disease management.
Although, in Europe, CAS is reimbursed in most but not all
countries, in the USA, the Centers for Medicare and Medicaid Ser-
vices’ reimbursement for CAS is limited to: (i) patients at high risk
for surgery with symptomatic stenosis .70% treated in qualified
institutions by qualified physicians using Food and Drug
Adminitration-approved stents and EPDs, and (ii) patients at high
risk for surgery with symptomatic stenosis .50% or asymptomatic
stenosis .80% enrolled in Investigational Device Exemption trials
or post-approval studies.
Conclusions
The results of our meta-analysis of the randomized trials compar-
ing CAS with CEA and enrolling almost exclusively symptomatic
patients show that CAS is inferior to CEA in terms of stroke or
death at 30 days. Beyond 30 days, long-term follow-up of the
trials previously reported suggest that both revascularization tech-
niques are equivalent in terms of stroke prevention. As a major
limitation, the majority of the randomized studies had inadequate
requirements in terms of endovascular expertise and did not
mandate the use of EPDs. Conversely, large-scale high-quality
registries have reported results in the range of current recommen-
dation for CEA even in patients at high risk for surgery. Until
further data become available, the performance of CAS should
be limited to protocols or centres of excellence and targeted
especially to patients at high risk for surgery.
Conflict of interest: none declared.
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